Imodiumliquicaps (Loperamide Hydrochloride)

Loperamide hydrochloride binds to μ‑opioid receptors in the intestinal wall, inhibiting the release of acetylcholine and other excitatory neurotransmitters. This slows intestinal motility, increases transit time, and allows greater water and electrolyte absorption, resulting in firmer stools.

The appropriate dose of Imodiumliquicaps is determined by a qualified healthcare professional based on the patient’s age, severity of symptoms, and clinical condition. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for loperamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Imodiumliquicaps.

To place an order, submit an enquiry on the Imodiumliquicaps product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imodiumliquicaps (loperamide) is a peripherally acting opioid that specifically reduces gut motility without significant central nervous system effects at therapeutic doses. Compared with adsorbent agents like bismuth subsalicylate, loperamide provides faster symptom control but requires caution in patients with infectious diarrhea where slowing transit could be harmful.

Store Imodiumliquicaps at ambient temperature below 25 °C. Keep the capsules in their original blister pack or container, protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Imodiumliquicaps are taken orally with a glass of water. The capsule should be swallowed whole and not crushed or chewed. Dosing intervals and total daily dose are set by the prescribing clinician based on the individual’s condition.

Serious risks include severe constipation that can progress to bowel obstruction, toxic megacolon in patients with inflammatory bowel disease, and cardiac arrhythmias when plasma concentrations become excessively high, especially in overdose situations. Prompt medical attention is required if these symptoms develop.

Imodiumliquicaps should be avoided in individuals with known hypersensitivity to loperamide, children under two years of age without medical advice, patients with acute dysentery or bacterial enterocolitis, and those with a history of severe hepatic impairment unless directed by a physician.